tiprankstipranks
Homology Medicines reports Q3 EPS (59c), consensus (47c)
The Fly

Homology Medicines reports Q3 EPS (59c), consensus (47c)

Reports Q3 revenue $802,000, consensus $860,000. "We remain on track to provide an update from our pheEDIT and juMPStart clinical trials, including site initiations and enrollment status, by the end of this year," said Albert Seymour, president and CEO of Homology Medicines. "With our recent pipeline prioritization, which included devoting resources to our ongoing clinical trials and select preclinical programs, Homology extended its cash runway into the fourth quarter of 2024 through key milestones across all programs. We continue to progress HMI-104, our lead GTx-mAb development candidate, through IND-enabling studies and believe that our optimized in vivo gene therapy development candidate for MLD, which has demonstrated the ability to cross the blood-brain-barrier following a single I.V. administration in preclinical studies, is differentiated from other approaches and makes it an attractive program for us to partner. Our work to bring first-in-class genetic medicine candidates forward for patients is ongoing, and we look forward to sharing our continued progress."

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on FIXX:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles